Individual question (Patent)
(iii)Specification and Claims
Q6. Format for the Specification
Q7. “Summary of Invention”
Q8. Essential Description in “Summary of Invention”
Q9. Plural Advantages
Q10. Claim Format
Q11. Multiple Dependency
Q12. Dependent Claims
Q13. Independent Claims
Q14. Claim Categories
Q21. Hypothetical Case and Discussion
Q22. Hypothetical Case and Discussion, Continued
Q23. How Internal Priority is Claimed
Q24. How is Double Patenting Avoided in the Case of the Internal Priority?
(vi)National Phase Entry of PCT Application
Q25. Nationalizing a PCT Application
(i) Statutory Requirements
Q36. Statutory Requirements
(ii) Unity of Invention
Q37. Unity of Invention
(iii) Enablement Requirement
Q38. Enablement requirement
Q39. Incorporation by Reference (IBR)
Q40. Number of Working Examples Needed to Satisfy the Enablement Requirement
Q41. Best Mode of Practicing the Invention
Q42. Advantageous effects or merits of the invention
(iv) Support Requirement
Q43. Extent of Disclosure in the Description and Drawings vs. Broadness of Claims
Q44. Undue Breadth (Claims Reading on Inoperative Subject Matter)
Q45. Burden of Proof on Support Requirement
(v) Clarity Requirement
Q46. Definition by Function
Q47. Definition of Terms
Q48.Recitation in Optional Form
Q49.Use of Ambiguous Terms
Q50.Claims Attempting to Define the Invention by Objectives to be Attained
Q51.Devices or Products with Limitations on Their Usage
Q53. Details of Novelty Requirements
Q54. Date of Publication of a Paper Submitted to a Journal
Q55. Oral Presentation
Q56. Grace Period
Q57. Presentation via Internet
Q58. Presentation Outside Japan
Q59. Procedures for Grace Period
Q60. Document published during Grace Period
(viii) Unpublished Prior Art (Disclosed in Unpublished Prior Application, Art. 29-2)
Q65. Unpublished Prior Art
Q66. Self-Collision (Exemption of Art. 29-2)
Q67. Foreign Unpublished Prior Art
Q68. Priority vs. Unpublished Prior Art 31
(ix) First to File Rule
Q69. First to File or First to Invent
(x) Specific Technical Field; Chemistry, Medicine and Biotechnology
Q70. Written Requirement for invention Concerning New Compound
Q71. Second Use of a Known Pharmaceutical Composition
Q72. Enablement Requirement for Medicine
Q73. Pharmacological Data
Q74. Physical-Chemical Data
Q75. Physical data or Test Data of a Compound
Q76. Later filed supportive Data
Q77. Paper or Prophetic Examples
Q78. Deposit of Microorganism or Biotech Material
Q79. Sequence Listing
Q80. Transgenic Animals
(xi) Specific Technical Field; CII (Computer Implemented Inventions)
Q81. Statutory Requirements for CII
Q82. Claim Categories of CII
Q83. Pure Algorithms or Program Listings
Q84. Drafting Claims and Specification
(i) Request for Substantive Examination
Q85. Who can file a request for substantive examination?
Q86. When the request should be filed?
Q87. Queuing Time for First Office Action
Q88. What kinds of Expeditions are available?
Q89. What is preferential examination?
Q90. What is accelerated examination?
Q91. What is super-accelerated examination?
Q92. Preferential Examination vs. Accelerated Examination
(iii) Office Action
Q93. Non-final OA vs. Final OA
Q94. Decision for Dismissal of Amendments
Q95. Notice of Reasons for Rejection on Violation of Requirements for Disclosure of Information on Prior Art Documents
Q96. Decision of rejection
Q97. Decision to Grant a Patent
Q98. Declarations to Support Broad Claims
Q101. When can amendments be filed?
Q102. Requirements for Amendment in response to non-final OA
Q103. Requirements for Amendment after Final OA
Q104. Requirements for Amendment When Filing an Appeal against Decision of Rejection Is there any restriction on amendments when filing an appeal against decision of rejection?
Q105. Amending Junior Application to Have it Read on Senior Application (Senior application and Junior application)
Q106. Amending Japanese claims to Parallel Issued Foreign Claims
Q107. Advantage of Paralleling Issued Foreign Claims
Q108. Further Narrowing the Paralleled Claims
Q109. New Matter
Q110. Amendment Changing Special Technical Feature
Q111. Amendments Challenged by Third Parties
(viii) Donation of Information
Q116. When can the information be submitted?
Q117. Who can submit the information?
Q118. What kind of information can be submitted?
Q119. Feedback of Donation of Information
Q120. Notification to Applicant of Donation of Information
Q121. Effect of Donation of Information
Q122. Disadvantages of Donation of information
(ix) Appeal against Examiner’s Decision of Rejection
Q123. Filing an Appeal against Examiner’s Decision of Rejection
Q125. Reconsideration by Examiner before Appeal
Q126. Shin-Jin (questioning/interrogation by an appeal board)
Q127. Documentary Proceeding
Q128. Appeal Decision
(xi)Registration, Term and Maintenance of Patent Right
Q133. Term and Maintenance of Patent right
Q134. How to Know Maintenance / Expiration of Registration
Q135. Registration of Extension of Term of Patent Right
III PATENT RIGHTS
Q137. Remedies for Patent Infringement
Q140. Monetary Recovery Before the Issuance of the Patent
Q141. Defendant’s Defense
Q142. Claim Interpretation
Q143. Doctrine of equivalence
Q144. Prosecution history estoppels
Q145. Doctrine of Claim Differentiation
Q146. Emphasis of Advantageous Effect
Q147. Reference Numerals in Claims
III.2 Trial for Patent Invalidation
Q148. Trial for patent invalidation
Q149. Grounds for Patent Invalidation
Q150. Who can request a trial for patent invalidation?
Q151. When can a trial for patent invalidation be requested?
Q153. Complaints against a Trial Decision
III.3 Trial for Correction
Q154. Trial for Correction
Q155. What kind of correction can be requested?
Q156. Who can file a request for a trial for correction?
Q157. When can a trial for correction be requested?
Q158. Complaints against a Trial Dismissal
III.4 Administrative Opinion, others
Q159. Administrative Opinion
Q160. Who can request an administrative opinion to the JPO?
Q161. Complaints against an Administrative Opinion
Q162. Trial for Invalidation of Registration of Extension of Term of Patent Right